<p>Barrington 分析师 Kevin Steinke 对 CCRN 股票维持中性立场，昨日给予持有评级。</p>
<h3>TipRanks 网络星期一促销</h3>
<ul>
<li>享受 TipRanks Premium 60% 的折扣，获取数据支持的洞察和研究工具，让您自信投资。</li>
<li>订阅 TipRanks 的智能投资者精选，通过我们高表现的模型投资组合查看我们的数据 - 现在也享受 60% 的折扣。</li>
</ul>
<p>Kevin Steinke 给予持有评级是由于与 Cross Country Healthcare 最近发展相关的多种因素。与 Aya Healthcare 的合并协议终止，主要是由于对美国联邦贸易委员会（FTC）可能提出挑战的担忧，给公司的战略方向带来了不确定性。作为行业的重要参与者，Aya Healthcare 决定退出合并，理由是 FTC 提出的重大竞争担忧，这可能会对竞争格局产生不利影响。</p>
<p>FTC 的担忧突显了医疗人员市场竞争减少的风险，这可能导致医院和患者的成本上升。尽管 Cross Country 努力遵守监管要求并延长合并协议的时间，但未能最终达成合并使公司不得不继续独立运营。这种情况导致了谨慎的前景，最终给予持有评级，因为公司在应对这些挑战并寻求稳定市场地位。</p>
<p>在昨日发布的另一份报告中，瑞银也对该股票维持持有评级，目标价为 9.00 美元。</p>

Cross Country医疗保健

<p>巴林顿分析师凯文·斯坦克（Kevin Steinke）在由于联邦贸易委员会（FTC）担忧而终止与 Aya Healthcare 的合并后，维持了对 Cross Country Healthcare（CCRN）股票的持有评级。合并的取消给 CCRN 的战略方向带来了不确定性。瑞银（UBS）也维持了持有评级，目标价为 9.00 美元</p>

<p>Barrington analyst Kevin Steinke has maintained their neutral stance on CCRN stock, giving a Hold rating yesterday.</p>
<div class="lb-trans"><p>Barrington 分析师 Kevin Steinke 对 CCRN 股票维持中性立场，昨日给予持有评级。</p>
</div><h3>TipRanks Cyber Monday Sale</h3>
<div class="lb-trans"><h3>TipRanks 网络星期一促销</h3>
</div><ul>
<li>Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.</li>
<li>Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio -  now also 60% off</li>
</ul>
<div class="lb-trans"><ul>
<li>享受 TipRanks Premium 60% 的折扣，获取数据支持的洞察和研究工具，让您自信投资。</li>
<li>订阅 TipRanks 的智能投资者精选，通过我们高表现的模型投资组合查看我们的数据 - 现在也享受 60% 的折扣。</li>
</ul>
</div><p>Kevin Steinke has given his Hold rating due to a combination of factors surrounding the recent developments with Cross Country Healthcare. The termination of the merger agreement with Aya Healthcare, primarily due to concerns about a potential challenge from the U.S. Federal Trade Commission (FTC), has introduced uncertainty into the company’s strategic direction. Aya Healthcare, being a major player in the industry, decided to withdraw from the merger, citing the significant competitive concerns raised by the FTC, which could have impacted the competitive landscape adversely.</p>
<div class="lb-trans"><p>Kevin Steinke 给予持有评级是由于与 Cross Country Healthcare 最近发展相关的多种因素。与 Aya Healthcare 的合并协议终止，主要是由于对美国联邦贸易委员会（FTC）可能提出挑战的担忧，给公司的战略方向带来了不确定性。作为行业的重要参与者，Aya Healthcare 决定退出合并，理由是 FTC 提出的重大竞争担忧，这可能会对竞争格局产生不利影响。</p>
</div><p>The FTC’s concerns highlighted the risk of reduced competition in the healthcare staffing market, which could have led to higher costs for hospitals and patients. Despite Cross Country’s efforts to comply with regulatory requirements and extend the merger agreement timeline, the inability to finalize the merger has left the company to continue operating independently. This situation has led to a cautious outlook, resulting in a Hold rating as the company navigates these challenges and seeks to stabilize its market position.</p>
<div class="lb-trans"><p>FTC 的担忧突显了医疗人员市场竞争减少的风险，这可能导致医院和患者的成本上升。尽管 Cross Country 努力遵守监管要求并延长合并协议的时间，但未能最终达成合并使公司不得不继续独立运营。这种情况导致了谨慎的前景，最终给予持有评级，因为公司在应对这些挑战并寻求稳定市场地位。</p>
</div><p>In another report released yesterday, UBS also maintained a Hold rating on the stock with a $9.00 price target.</p>
<div class="lb-trans"><p>在昨日发布的另一份报告中，瑞银也对该股票维持持有评级，目标价为 9.00 美元。</p>
</div>

Cross Country 医疗保健在终止与 Aya Healthcare 的合并后面临不确定性